Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Bought by True Wind Capital Management L.P.

True Wind Capital Management L.P. lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 18.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,861,007 shares of the company’s stock after buying an additional 2,130,386 shares during the quarter. Cellebrite DI makes up about 87.1% of True Wind Capital Management L.P.’s holdings, making the stock its largest position. True Wind Capital Management L.P. owned about 6.73% of Cellebrite DI worth $305,358,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Quarry LP purchased a new stake in Cellebrite DI in the 3rd quarter valued at about $27,000. Advisors Asset Management Inc. grew its holdings in Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after buying an additional 1,742 shares during the period. R Squared Ltd purchased a new stake in Cellebrite DI in the 4th quarter valued at about $100,000. Venturi Wealth Management LLC grew its holdings in Cellebrite DI by 28.6% in the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company’s stock valued at $152,000 after buying an additional 2,000 shares during the period. Finally, MQS Management LLC purchased a new stake in Cellebrite DI in the 3rd quarter valued at about $294,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Up 0.3 %

Shares of CLBT stock opened at $18.56 on Friday. The stock has a 50-day simple moving average of $22.31 and a 200 day simple moving average of $19.57. Cellebrite DI Ltd. has a fifty-two week low of $10.24 and a fifty-two week high of $26.30. The stock has a market capitalization of $3.82 billion, a P/E ratio of -13.35, a P/E/G ratio of 4.27 and a beta of 1.47.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Craig Hallum lifted their price target on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Lake Street Capital lifted their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a report on Friday, February 14th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of Cellebrite DI in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. boosted their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI currently has a consensus rating of “Buy” and an average price target of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.